Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Issue 1 (January 2012)

Record Type:: Journal Article
Title:: Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Issue 1 (January 2012)
Main Title:: Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer
Authors:: Bedoya, Diego J
Mitsiades, Nicholas
Abstract:
Is Part Of:: Expert review of anticancer therapy. Volume 12:Issue 1(2012)
Journal:: Expert review of anticancer therapy
Issue:: Volume 12:Issue 1(2012)
Issue Display:: Volume 12, Issue 1 (2012)
Year:: 2012
Volume:: 12
Issue:: 1
Issue Sort Value:: 2012-0012-0001-0000
Page Start:: 1
Page End:: 3
Publication Date:: 2012-01
Subjects:: abiraterone -- androgen ablation therapy -- androgen-deprivation therapy -- androgen receptor -- castration-resistant prostate cancer -- combination therapy -- CYP17 -- drug resistance -- MDV3100 -- prostate cancer
Cancer -- Treatment -- Periodicals
616.99406
Journal URLs:: http://informahealthcare.com ↗
http://www.future-drugs.com/loi/era ↗
DOI:: 10.1586/era.11.196 ↗
Languages:: English
ISSNs:: 1473-7140
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3842.002982
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store
Ingest File:: 16220.xml